[1] Gurbel P A, Becker R C, Mann K G, et al. Platelet function monitoring in patients with coronary artery disease[J]. J Am Coll Cardiol, 2007, 50(19):1822-1834. [2] Harrison P. Platelet function analysis[J]. Blood Rev,. 2005, 19(2): 111-123. [3] 李涛,屈晨雪,王建中,等.光学比浊法血小板聚集试验的标准化研究[J]. 中国实验诊断学, 2010, 14(12):2041-2043. [4] 尹小明,赵诗云,彭旦明,等. SD大鼠血小板聚集实验测定方法的研究[J]. 南昌大学学报(医学版),2013, 53(8):6-7. [5] Ma L, Hollenberg M D, Wallace J L. Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist [J]. British Journal of Pharmacology,2001, 134(4):701- 704. [6] Franchini M, Mannucci P M. New antiplatelet agents:why they are needed [J]. European Journal of Internal Medicine.,2009, 20(8): 733-738. [7] Moffat K A, Ledford-Kraemer M R, Nichols W L, et al. Variability in clinical laboratory practice in testing for disorders of platelet function Results of two surveys of the North American Specialized Coagulation Laboratory Association[J]. Thromb Haemost, 2005, 93(3):549-553. [8] Linnemann B, Schwonberg J, Mani H, et al. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary[J]. Journal of Throm-bosis and Haemostasis,2008, 6(4):677-683. [9] Mani H, Luxembourg B, Kl ffling C, et al. Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements[J]. J Clin Pathol,2005, 58(7):747-750. [10] Zhou L, Schmaier A H. Platelet Aggregation Testing in Platelet-Rich Plasma: Description of Procedures With the Aim to Develop Standards in the Field[J]. Am J Clin Pathol,2005, 123(2):172-183. |